Spanish VC Ysios Capital Launches €100M Fund To Support Biotech Startups

The fund has already achieved its first close, with backing from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte programme, which promotes investment in high-potential innovative businesses. The fund will be led by Ysios Capital Managing Partner Joan Perelló, together with partner Arturo Urrios.

Founded in 2008, Ysios Capital manages more than €400 million in assets across three venture capital funds and also serves as investment advisor to the listed Telescope Biotech Fund, managed by Andbank Wealth Management.

The firm provides private equity financing to early- and mid-stage life sciences companies developing therapies that can make a meaningful difference for patients, particularly in areas with significant unmet medical needs.

InceptionBio will focus on identifying, developing, and building new companies based on high-quality scientific research, with a strong emphasis on Spain. The fund will primarily target technology transfer opportunities and early-stage ventures, enabling Ysios to collaborate closely with universities, research centres, and scientific entrepreneurs to accelerate the conversion of scientific discoveries into new therapies.

Read Also - UK-based Keith Raises €2.3M Seed Round Led By Backed VC

Support from CDTI-Innvierte strengthens public-private collaboration in a sector that is critical to Spain’s biotech ecosystem. According to the firm, this partnership will help speed up technology transfer, foster the growth of innovation-driven companies, and enhance the competitiveness of Spain’s R&D landscape.

The fund already has a pipeline of investment opportunities under advanced review and aims to support the creation of at least three new biotech companies in 2026.

Ysios states that InceptionBio’s strategy includes building companies around scientific assets sourced from universities and research institutions, while also identifying and attracting international assets that can be developed within Spain.

Through this approach, Ysios aims to strengthen Spain’s biotech ecosystem and position the country as a leading hub in the sector. The initiative complements the firm’s existing investment strategy by expanding its involvement at the earliest stages reinforcing its capacity to support biomedical innovation from company creation through to later-stage development.

“We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them. InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain,” said Arturo Urrios, Partner at Ysios Capital.

“Spain has world-class science and a unique opportunity to translate that science into globally impactful BioTech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients,” said Joan Perelló, Managing Partner at Ysios Capital.